
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Heartburn cost-effectiveness of therapy
Introduction
Overview
Overview
The use of proton pump inhibitors for 8 weeks associated with lifestyle modifications is a cost-saving strategy in patients with heartburn and gastroesophageal reflux disease (GERD).
Cost-effectiveness of Therapy
Cost-effectiveness of Therapy
- A study from Stanford University School of Medicine revealed that “an 8-wk course of PPIs for initial symptom relief, followed by repeat courses of therapy initiated when symptoms recur, is more cost-effective than step-up or step-down strategies, or continuous therapy with either H2RAs or PPIs.”[1]
- Costs estimated for the treatment of GERD according to the medication and regimen – considering mild GERD from 40yrs until death (in 1999 US dollars):
- Lifestyle – $0
- PPI-on-demand – $26,167
- H2RA-PPI – $27,846
- H2RA – $29,965
- Step down – $37,641
- PPI, continuous – $41,112
- Laparoscopic Nissen fundoplication (includes 2-day hospital stay) – approximately – $11,064.87
- Considering that the complications Barrett’s esophagus may lead to esophageal cancer which presents with a much more costlier treatment, the on-demand PPI-therapy is the most cost-effective treatment available. The paper also stated that even thought it is the most cost-effective choice, it was the least used. The study was performed in 2000, which may cause its results to vary dramatically in more recent times.
References
References
- ↑ Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G (2000). “A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease”. Am J Gastroenterol. 95 (2): 395–407. doi:10.1111/j.1572-0241.2000.01759.x. PMID 10685741.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]
